首頁 > 市場調查報告書 > 製藥

醫藥品原料藥

市場調查報告書

商品編碼

2020323

藥品活性成分（API）市場規模、佔有率、成長及全球產業分析：按類型、應用和地區分類，並提供2026-2034年的洞察和預測

Active Pharmaceutical Ingredient (API) Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034

出版日期: 2026年03月16日 | 出版商:

Fortune Business Insights Pvt. Ltd. | 英文 138 Pages | 商品交期: 請詢問到貨日

價格

簡介目錄圖表

活性藥物成分（API）市場的成長要素

2025年全球活性藥物成分（API）市值為2,452.6億美元，預計2026年將成長至2,612.8億美元。預計到2034年，該市場將達到4,577.5億美元，在預測期（2026-2034年）內複合年成長率為7.26%。

受創新藥物需求旺盛和慢性病盛行率上升的推動，預計到 2025 年，北美將以 47.22% 的市佔率引領全球市場。

市場概覽

原料藥（API），也稱為原料藥，是藥物發揮治療作用的主要成分。它們透過化學或生物方法生產，是藥物製劑的基礎。

受先進治療方法需求不斷成長、個人化醫療日益受到重視以及製藥和生物技術公司持續創新的推動，市場正經歷穩步成長。此外，新型藥物遞送系統的廣泛應用也進一步促進了全球原料藥的需求。

新冠疫情的影響

新冠疫情初期對原料藥市場造成了負面影響，尤其是在中國，工廠停工和原料供應鏈中斷是主要原因。選擇性手術需求的減少也影響了藥物消費。

然而，對救命藥物（尤其是呼吸系統藥物）的強勁需求，以及全球生產設施的重新開放，使得疫情後市場得以復甦。

市場趨勢

API生產外包增加

市場主要趨勢之一是原料藥生產外包給中國和印度等國家的情況日益增加。製藥公司正逐步放棄內部生產，以降低成本，並更專注於藥物發現和研發。

合約開發和生產組織 (CDMO) 透過提供專業知識、基礎設施和擴充性，變得越來越重要，從而推動市場成長。

市場促進因素

藥品需求不斷成長

癌症、心血管疾病和糖尿病等慢性疾病在全球造成的負擔日益加重，顯著增加了對藥品的需求，從而推動了原料藥市場的發展。

此外，新興國家醫療保健支出不斷成長，診斷率不斷提高，導致患者群體不斷擴大，進而增加了對學名藥和品牌藥的需求。

生物製藥需求不斷成長

向生物製藥和生物相似藥的轉型也是主要的成長要素。生物製藥原料藥因其在治療複雜疾病方面的有效性、監管核准的增加以及生物技術的創新而備受關注。

市場限制因素

價格波動和監管挑戰

新興市場定價政策的不確定性以及對有限原料供應商的依賴會阻礙市場成長。價格快速上漲和供應鏈中斷給製造商帶來挑戰。

此外，各地區嚴格的監管要求使得原料藥的生產和核准過程變得複雜且耗時。

細分分析

按類型

到 2026 年，在強大的研發投入和高效藥物創新推動下，品牌 API 市場將佔據主導地位，市佔率達到 62.10%。

然而，由於專利到期和對經濟實惠的藥品的需求不斷成長，非專利藥原料藥市場預計將快速成長。

透過合成方法

到 2026 年，合成 API 領域將憑藉其低廉的製造成本和簡單的製造程序，以 70.52% 的市佔率引領市場。

另一方面，隨著對先進生物製藥的需求不斷成長，生物製劑原料藥預計將以更快的速度成長。

區域洞察

北美洲

預計北美市場規模將在2025年達到1,158.1億美元，2026年達到1,227.4億美元。這一成長是由慢性病的高發病率和對研發的大力投入所推動的。

歐洲

預計到 2025 年，歐洲的市場規模將達到 567.8 億美元，到 2026 年將達到 606.1 億美元，這得益於藥品生產和研發舉措的增加。

亞太地區

預計亞太地區2025年市場規模將達533.5億美元，2026年將成長至573.1億美元。該地區成長速度最快，這得益於其低廉的製造成本和強勁的外包趨勢。

世界其他地區

預計到 2025 年，該地區的價值將達到 193.2 億美元，到 2026 年將達到 206.1 億美元，這主要得益於基礎設施的改善和監管的進步。

儘管面臨價格波動和監管複雜性等挑戰，但外包、技術進步和新興經濟體的成長為市場帶來了巨大的機會。向生物製藥和個人化醫療的轉型將進一步塑造原料藥產業的未來，並成為全球醫療保健發展的重要支柱。

The market is witnessing steady growth due to rising demand for advanced therapeutics, increasing focus on personalized medicine, and continuous innovations by pharmaceutical and biotechnology companies. Additionally, the growing adoption of novel drug delivery systems is further strengthening the demand for APIs globally.

Impact of COVID-19

The COVID-19 pandemic had a negative impact on the API market initially due to factory shutdowns, especially in China, and disruptions in raw material supply chains. Reduced demand for elective procedures also affected pharmaceutical consumption.

However, the market rebounded post-pandemic due to strong demand for life-saving drugs, particularly respiratory medicines, and the reopening of manufacturing facilities worldwide.

Market Trends

Rising Outsourcing of API Manufacturing

One of the key trends in the market is the increasing outsourcing of API production to countries such as China and India. Pharmaceutical companies are shifting away from in-house manufacturing to reduce costs and focus more on drug discovery and development.

Contract Development and Manufacturing Organizations (CDMOs) are gaining importance as they offer specialized expertise, infrastructure, and scalability, thereby boosting market growth.

Market Drivers

Growing Demand for Pharmaceuticals

The rising global burden of chronic diseases such as cancer, cardiovascular disorders, and diabetes is significantly increasing the demand for pharmaceutical drugs, thereby driving the API market.

In addition, growing healthcare expenditure and improved diagnosis rates in emerging economies are expanding the patient pool, leading to higher demand for both generic and branded drugs.

Increasing Demand for Biologics

The shift toward biologics and biosimilars is another major growth driver. Biological APIs are gaining traction due to their effectiveness in treating complex diseases, supported by increasing regulatory approvals and innovation in biotechnology.

Market Restraints

Price Fluctuations and Regulatory Challenges

Unpredictable pricing policies in emerging markets and dependency on limited suppliers for raw materials can hinder market growth. Sudden price hikes and supply chain disruptions pose challenges for manufacturers.

Additionally, stringent regulatory requirements across different regions make API production and approvals complex and time-consuming.

Segmentation Analysis

By Type

The branded API segment dominated the market with a 62.10% share in 2026, driven by strong R&D investments and innovation in high-potency drugs.

However, the generic API segment is expected to grow rapidly due to patent expirations and increasing demand for cost-effective medicines.

By Synthesis

The synthetic API segment led the market with a 70.52% share in 2026, owing to lower production costs and simpler manufacturing processes.

Meanwhile, biological APIs are projected to grow at a faster rate due to rising demand for advanced biologic therapies.

Regional Insights

North America

North America generated USD 115.81 billion in 2025 and is expected to reach USD 122.74 billion in 2026. Growth is driven by high prevalence of chronic diseases and strong R&D investments.

Europe

Europe accounted for USD 56.78 billion in 2025 and is projected to reach USD 60.61 billion in 2026, supported by increasing pharmaceutical production and research initiatives.

Asia Pacific

Asia Pacific held USD 53.35 billion in 2025 and is expected to grow to USD 57.31 billion in 2026. The region is the fastest-growing due to low manufacturing costs and strong outsourcing trends.

Rest of the World

This region was valued at USD 19.32 billion in 2025 and is projected to reach USD 20.61 billion in 2026, driven by improving infrastructure and regulatory developments.

Competitive Landscape

The API market is highly fragmented with key players such as AbbVie Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Amgen Inc., Cipla Inc., and Sun Pharmaceutical Industries Ltd.

These companies focus on strategic partnerships, acquisitions, and expansion of manufacturing capabilities to strengthen their global presence.

Conclusion

In conclusion, the global API market is set for steady and sustained growth, rising from USD 245.26 billion in 2025 to USD 457.75 billion by 2034. The growth is primarily driven by increasing demand for pharmaceuticals, rising chronic disease burden, and expanding biologics segment.

Despite challenges such as pricing volatility and regulatory complexities, the market presents strong opportunities through outsourcing, technological advancements, and growth in emerging economies. The shift toward biologics and personalized medicine will further shape the future of the API industry, making it a critical pillar of global healthcare development.

Segmentation

By Type

Generic API
Branded API

By Synthesis

Biological API
Synthetic API

By Geography

North America (By Type, By Synthesis, and By Country)
- U.S.
- Canada
Europe (By Type, By Synthesis, and By Country/Sub-Region)
- U.K.
- Germany
- France
- Italy
- Spain
- Scandinavia
- Rest of Europe
Asia Pacific (By Type, By Synthesis, and By Country/Sub-Region)
- Japan
- China
- India
- Australia
- Southeast Asia
- Rest of Asia Pacific
Rest of World (By Type, and By Synthesis)

Table of Content

1. Introduction

1.1. Research Scope
1.2. Market Segmentation
1.3. Research Methodology
1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Market Trends

4. Key Insights

4.1. Prevalence of Key Chronic Diseases, By Key Countries/Regions, 2025
4.2. Key Industry Developments - Partnerships, Mergers, And Acquisitions
4.3. Therapeutic Applications of the Different Types of Active Pharmaceutical Ingredient
4.4. Impact of COVID-19 on the Market

5. Global Active Pharmaceutical Ingredient Market Analysis, Insights and Forecast, 2021-2034

5.1. Market Analysis, Insights and Forecast - By Type
- 5.1.1. Generic API
- 5.1.2. Branded API
5.2. Market Analysis, Insights and Forecast - By Synthesis
- 5.2.1. Biological API
- 5.2.2. Synthetic API
5.3. Market Analysis, Insights and Forecast - By Region
- 5.3.1. North America
- 5.3.2. Europe
- 5.3.3. Asia Pacific
- 5.3.4. Rest of World

6. North America Active Pharmaceutical Ingredient Market Analysis, Insights and Forecast, 2021-2034

6.1. Market Analysis, Insights and Forecast - By Type
- 6.1.1. Generic API
- 6.1.2. Branded API
6.2. Market Analysis, Insights and Forecast - By Synthesis
- 6.2.1. Biological API
- 6.2.2. Synthetic API
6.3. Market Analysis, Insights and Forecast - By Country
- 6.3.1. U.S.
- 6.3.2. Canada

7. Europe Active Pharmaceutical Ingredient Market Analysis, Insights and Forecast, 2021-2034

7.1. Market Analysis, Insights and Forecast - By Type
- 7.1.1. Generic API
- 7.1.2. Branded API
7.2. Market Analysis, Insights and Forecast - By Synthesis
- 7.2.1. Biological API
- 7.2.2. Synthetic API
7.3. Market Analysis, Insights and Forecast - By Country/Sub-Region
- 7.3.1. U.K.
- 7.3.2. Germany
- 7.3.3. France
- 7.3.4. Italy
- 7.3.5. Spain
- 7.3.6. Scandinavia
- 7.3.7. Rest of Europe

8. Asia Pacific Active Pharmaceutical Ingredient Market Analysis, Insights and Forecast, 2021-2034

8.1. Market Analysis, Insights and Forecast - By Type
- 8.1.1. Generic API
- 8.1.2. Branded API
8.2. Market Analysis, Insights and Forecast - By Synthesis
- 8.2.1. Biological API
- 8.2.2. Synthetic API
8.3. Market Analysis, Insights and Forecast - By Country/Sub-Region
- 8.3.1. Japan
- 8.3.2. China
- 8.3.3. India
- 8.3.4. Australia
- 8.3.5. Southeast Asia
- 8.3.6. Rest of Asia Pacific

9. Rest of World Active Pharmaceutical Ingredient Market Analysis, Insights and Forecast, 2021-2034

9.1. Market Analysis, Insights and Forecast - By Type
- 9.1.1. Generic API
- 9.1.2. Branded API
9.2. Market Analysis, Insights and Forecast - By Synthesis
- 9.2.1. Biological API
- 9.2.2. Synthetic API

10. Competitive Analysis

10.1. Global Market Share Analysis (2025)
10.2. Company Profiles
- 10.2.1. Teva Pharmaceutical Industries Ltd
  - 10.2.1.1. Overview
  - 10.2.1.2. Products & Services
  - 10.2.1.3. SWOT Analysis
  - 10.2.1.4. Recent Developments
  - 10.2.1.5. Strategies
  - 10.2.1.6. Financials (Based on Availability)
- 10.2.2. AbbVie Inc.
  - 10.2.2.1. Overview
  - 10.2.2.2. Products & Services
  - 10.2.2.3. SWOT Analysis
  - 10.2.2.4. Recent Developments
  - 10.2.2.5. Strategies
  - 10.2.2.6. Financials (Based on Availability)
- 10.2.3. Abbott
  - 10.2.3.1. Overview
  - 10.2.3.2. Products & Services
  - 10.2.3.3. SWOT Analysis
  - 10.2.3.4. Recent Developments
  - 10.2.3.5. Strategies
  - 10.2.3.6. Financials (Based on Availability)
- 10.2.4. Aurobindo Pharma
  - 10.2.4.1. Overview
  - 10.2.4.2. Products & Services
  - 10.2.4.3. SWOT Analysis
  - 10.2.4.4. Recent Developments
  - 10.2.4.5. Strategies
  - 10.2.4.6. Financials (Based on Availability)
- 10.2.5. Cipla Inc.
  - 10.2.5.1. Overview
  - 10.2.5.2. Products & Services
  - 10.2.5.3. SWOT Analysis
  - 10.2.5.4. Recent Developments
  - 10.2.5.5. Strategies
  - 10.2.5.6. Financials (Based on Availability)
- 10.2.6. Dr. Reddy's Laboratories Ltd
  - 10.2.6.1. Overview
  - 10.2.6.2. Products & Services
  - 10.2.6.3. SWOT Analysis
  - 10.2.6.4. Recent Developments
  - 10.2.6.5. Strategies
  - 10.2.6.6. Financials (Based on Availability)
- 10.2.7. Sun Pharmaceutical Industries Ltd
  - 10.2.7.1. Overview
  - 10.2.7.2. Products & Services
  - 10.2.7.3. SWOT Analysis
  - 10.2.7.4. Recent Developments
  - 10.2.7.5. Strategies
  - 10.2.7.6. Financials (Based on Availability)
- 10.2.8. Amgen Inc.
  - 10.2.8.1. Overview
  - 10.2.8.2. Products & Services
  - 10.2.8.3. SWOT Analysis
  - 10.2.8.4. Recent Developments
  - 10.2.8.5. Strategies
  - 10.2.8.6. Financials (Based on Availability)
- 10.2.9. Biocon
  - 10.2.9.1. Overview
  - 10.2.9.2. Products & Services
  - 10.2.9.3. SWOT Analysis
  - 10.2.9.4. Recent Developments
  - 10.2.9.5. Strategies
  - 10.2.9.6. Financials (Based on Availability)
- 10.2.10. Mylan N.V.
  - 10.2.10.1. Overview
  - 10.2.10.2. Products & Services
  - 10.2.10.3. SWOT Analysis
  - 10.2.10.4. Recent Developments
  - 10.2.10.5. Strategies
  - 10.2.10.6. Financials (Based on Availability)

簡介目錄圖表

List of Tables

Table 1: Global Active Pharmaceutical Ingredient Market Revenue (USD billion) Forecast, by Type, 2021-2034
Table 2: Global Active Pharmaceutical Ingredient Market Revenue (USD billion) Forecast, by Synthesis, 2021-2034
Table 3: Global Active Pharmaceutical Ingredient Market Revenue (USD billion) Forecast, by Region, 2021-2034
Table 4: North America Active Pharmaceutical Ingredient Market Revenue (USD billion) Forecast, by Type, 2021-2034
Table 5: North America Active Pharmaceutical Ingredient Market Revenue (USD billion) Forecast, by Synthesis, 2021-2034
Table 6: North America Active Pharmaceutical Ingredient Market Revenue (USD billion) Forecast, By Country, 2021-2034
Table 7: Europe Active Pharmaceutical Ingredient Market Revenue (USD billion) Forecast, by Type, 2021-2034
Table 8: Europe Active Pharmaceutical Ingredient Market Revenue (USD billion) Forecast, by Synthesis, 2021-2034
Table 9: Europe Active Pharmaceutical Ingredient Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
Table 10: Asia Pacific Active Pharmaceutical Ingredient Market Revenue (USD billion) Forecast, by Type, 2021-2034
Table 11: Asia Pacific Active Pharmaceutical Ingredient Market Revenue (USD billion) Forecast, by Synthesis, 2021-2034
Table 12: Asia Pacific Active Pharmaceutical Ingredient Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
Table 13: Rest of World Active Pharmaceutical Ingredient Market Revenue (USD billion) Forecast, by Type, 2021-2034
Table 14: Rest of World Active Pharmaceutical Ingredient Market Revenue (USD billion) Forecast, by Synthesis, 2021-2034

List of Figures

Figure 01: Global Active Pharmaceutical Ingredient Market Revenue Breakdown (USD billion, %) by Region, 2026 & 2034
Figure 02: Global Active Pharmaceutical Ingredient Market Value Share (%), By Type, 2026 & 2034
Figure 03: Global Active Pharmaceutical Ingredient Market Value Share (%), By Synthesis, 2026 & 2034
Figure 04: Global Active Pharmaceutical Ingredient Market Value (USD billion), By Region, 2026 & 2034
Figure 05: North America Active Pharmaceutical Ingredient Market Value (USD billion), By Type, 2026 & 2034
Figure 06: North America Active Pharmaceutical Ingredient Market Value Share (%), By Type, 2025
Figure 07: North America Active Pharmaceutical Ingredient Market Value (USD billion), By Synthesis, 2026 & 2034
Figure 08: North America Active Pharmaceutical Ingredient Market Value Share (%), By Synthesis, 2025
Figure 09: North America Active Pharmaceutical Ingredient Market Value (USD billion), By Country, 2026 & 2034
Figure 10: North America Active Pharmaceutical Ingredient Market Value Share (%), By Country, 2025
Figure 11: Europe Active Pharmaceutical Ingredient Market Value (USD billion), By Type, 2026 & 2034
Figure 12: Europe Active Pharmaceutical Ingredient Market Value Share (%), By Type, 2025
Figure 13: Europe Active Pharmaceutical Ingredient Market Value (USD billion), By Synthesis, 2026 & 2034
Figure 14: Europe Active Pharmaceutical Ingredient Market Value Share (%), By Synthesis, 2025
Figure 15: Europe Active Pharmaceutical Ingredient Market Value (USD billion), By Country/Sub-Region, 2026 & 2034
Figure 16: Europe Active Pharmaceutical Ingredient Market Value Share (%), By Country/Sub-Region, 2025
Figure 17: Asia Pacific Active Pharmaceutical Ingredient Market Value (USD billion), By Type, 2026 & 2034
Figure 18: Asia Pacific Active Pharmaceutical Ingredient Market Value Share (%), By Type, 2025
Figure 19: Asia Pacific Active Pharmaceutical Ingredient Market Value (USD billion), By Synthesis, 2026 & 2034
Figure 20: Asia Pacific Active Pharmaceutical Ingredient Market Value Share (%), By Synthesis, 2025
Figure 21: Asia Pacific Active Pharmaceutical Ingredient Market Value (USD billion), By Country/Sub-Region, 2026 & 2034
Figure 22: Asia Pacific Active Pharmaceutical Ingredient Market Value Share (%), By Country/Sub-Region, 2025
Figure 23: Rest of World Active Pharmaceutical Ingredient Market Value (USD billion), By Type, 2026 & 2034
Figure 24: Rest of World Active Pharmaceutical Ingredient Market Value Share (%), By Type, 2025
Figure 25: Rest of World Active Pharmaceutical Ingredient Market Value (USD billion), By Synthesis, 2026 & 2034
Figure 26: Rest of World Active Pharmaceutical Ingredient Market Value (USD %), By Synthesis 2025
Figure 27: Global Active Pharmaceutical Ingredient Market Share (%), by Company, 2025